AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia.
AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson’s medicinal products have not given satisfactory results. PRODUODOPA is the first-and-only…